RecruitingNCT07547787
A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
An Extension Study for Collecting Long-term Follow-up Data of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Sponsor
Akeso
Enrollment
610 participants
Start Date
Dec 26, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Eligibility
Inclusion Criteria4
- Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
- Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
- Agree to proceed with the extended follow-up procedures.
- This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.
Exclusion Criteria1
- None
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07547787